Elesclomol
- Generic Name
- Elesclomol
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N4O2S2
- CAS Number
- 488832-69-5
- Unique Ingredient Identifier
- 6UK191M53P
- Background
Elesclomol is a novel, injectable, drug candidate that kills cancer cells by elevating oxidative stress levels beyond a breaking point, triggering programmed cell death. In preclinical models elesclomol showed potent killing of a broad range of cancer cell types at high doses, and an ability to strongly enhance the efficacy of certain chemotherapy agents, with minimal additional toxicity, at moderate doses. It is being developed by Synta Pharmaceuticals.
- Indication
Investigated for use/treatment in melanoma.
Immune-Based AML Subgroups Reveal Prognostic and Therapeutic Implications
• Researchers identified two immune-based subgroups in acute myeloid leukemia (AML), G1 and G2, with distinct immune infiltration and mutational profiles.
• The G1 subgroup, characterized by higher immune infiltration and specific mutations, was associated with poorer prognosis compared to the G2 subgroup.
• The study suggests potential therapeutic strategies based on subgroup-specific drug sensitivities, with G1 showing sensitivity to elesclomol and panobinostat but resistance to venetoclax.
• These findings refine AML risk stratification and offer guidance for precision medicine approaches, potentially improving treatment outcomes.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath